卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌疗效观察

Efficacy of Camrelizumab Combined with First-line Chemotherapy in Treatment of Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer

目的:观察卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌(NSCLC)的疗效。方法:选取我院收治的88例晚期/转移性非鳞状NSCLC患者,按照随机数字表法分成对照组(44例)与观察组(44例)。对照组给予常规化疗方案治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,连续化疗3个疗程后对比两组免疫因子及毒副反应情况。结果:观察组总生存期(OS)、无进展生存期(PFS)均高于对照组,差异具有统计学意义(P<0.05);CD3^+、CD4^+、CD4^+/CD8^+水平高于对照组,CD8^+水平低于对照组,差异具有统计学意义(P<0.05);毒副反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状NSCLC,可以改善患者的OS、PFS,延缓免疫功能下降,疗效增加而毒副作用未明显增加,值得推广。

Objective:To investigate the efficacy of camrelizumab combined with first-line chemotherapy in treatment of advanced/metastatic non-squamous non-small cell lung cancer(NSCLC).Methods:88 patients with advanced/metastatic non-squamous NSCLC who admitted in the hospital were divided into control group(44 cases)and observation group(44 cases)according to random number table.Control group was given routine chemotherapy,and observation group was treated with camrelizumab based on control group.The immune factors and toxic-side effects were compared between two groups after 3 courses of chemotherapy.Results:The overall survival(OS)and progression free survival(PFS)in observation group were higher than those in control group(P<0.05);The levels of CD3^+,CD4^+and CD4^+/CD8^+in observation group were higher than those in control group,and the level of CD8^+in observation group was lower than that in control group(P<0.05);There was no statistical difference between observation group and control group in the incidence of toxic-side effect(P>0.05).Conclusion:Camrelizumab combined with first-line chemotherapy in treatment of advanced/metastatic non-squamous NSCLC can improve OS and PFS of patients,and enhance efficacy without significant increase in toxic-side effects,which is worthy of promotion.